Aastrom Biosciences About
Aastrom Biosciences: Aastrom Biosciences, Inc. (NasdaqSC:
ASTM) is developing proprietary adult stem cell-based products for the regenerative
repair of damaged human tissues and other medical disorders. Aastrom's strategic
position in the tissue regeneration and cell therapy sectors is enabled by its
proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor
cells, and the AastromReplicell® System, an industry-unique automated cell production
platform used to produce cells for clinical use. Together TRCs and the AastromReplicell
System provide a foundation that the Company is leveraging to produce multiple
Prescription Cell Products, the first of which is now in the clinical stage in
the U.S. and EU. TRCs are the core component of the Prescription Cell Products
Aastrom is developing for the bone grafting, peripheral vascular disease and cartilage
markets. The company also markets the AastromReplicell System and disposable dendritic
cell production kits to researchers and institutions developing vaccines to treat
cancer and infectious diseases, under its Cell Production Products line. To
date, over 3,000 stem cell production runs have been completed successfully. In
multi-center clinical trials involving over 160 patients, TRCs have been demonstrated
to be safe and reliable, and to regenerate normal healthy tissues. Stem cells
are human cells that have the capability to form multiple, or in some cases, all
types of tissues. Therefore, stem cells represent potentially powerful agents
for repairing damaged or diseased tissues. Stem cells are found in every individual's
bone marrow; access is simple and without controversy. Stem cells are also found
in embryonic tissues as part of a developing fetus, but access to these cells
has proven controversial. As a result, researchers seeking potential novel treatments
for a wide variety of diseases and disorders are increasingly investigating bone
marrow-derived "adult stem cells" in clinical research. Aastrom's stem cell therapeutics
program uses adult stem cells, typically derived from the patient's own bone marrow,
which can be successfully grown to the increased number of cells required for
certain clinical applications, using the patented technology embodied in the AastromReplicell
System. Pipeline
Chart for Aastrom Biosciences Pipeline:
Isatoribine
(ANA245) Hepatitis
C ANA
380 Hepatitis
B Isatoribine
(ANA245) Addition
Indications Oral
Prodrug ANA971 Additional
Indications Oral
Prodrug ANA975 Hepatitis
C
More on Aastrom Biosciences: